Read on to find out why dividend seekers can confidently add Pfizer and Bristol Myers Squibb to their portfolios. Pfizer has encountered some issues in recent years. Sales of its coronavirus products fell off a cliff,

February investments fell below $1,000, mainly in BDCs like Owl Rock Capital and Ares Capital, boosting annual dividend income by $77.

Market uncertainty and volatility have knocked down most growth bets. Investors are now looking for dividend stocks in anticipation of escalating trade wars. Treasury yields have peaked out and have retreated a little in the past few months,